Oncology

Latest News

Tech Updates: McKesson Launches Precision Oncology Consortium; Financing for RISA Labs PA Platform

By Mary Caffrey

April 17th 2025

These advances are designed to improve uptake of biomarker-driven cancer care and reduce treatment delays.

Making Novel Cancer Therapies Available Requires Choices Because Resources Are Limited

By Kyle Munz

April 14th 2025

Businessman shows medical network wooden block for health, medicine, insurance, healthcare, care, concept. Medical technology services to solve public - ภัทรชัย รัตนชัยวงค์ - stock.adobe.com.jpeg

NCCN Data Find Racial, Socioeconomic Disparities in Quality of Care for Metastatic Pancreatic Cancer

By Giuliana Grossi

April 9th 2025

Comparing Breast Cancer Treatment Outcomes Between Fee-for-Service and Medicare Advantage

By Galen Shearn-Nance, BS
Rishi R. Sachdev, BS

April 4th 2025

Woman with keloid on shoulder | Image credit: weerajata – stock.adobe.com

Deep Learning Tool Differentiates Keloids From Malignant Lesions Without Dermoscopy

By Hayden E. Klein

April 2nd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

August 10th 2017

Genetic Counselors Save Costs Across the Genetic Testing Spectrum

Joy Larsen Haidle, MS, CGC Darci L. Sternen, MS, CGC Jane A. Dickerson, PhD Amelia Mroch, MS, CGC Denise F. Needham, MS, CGC Christine M. Riordan, MS, CGC Michele C. Kieke, PhD, MS, CGC

Genetic counselors (GCs) increasingly serve a variety of roles across the healthcare spectrum, including test utilization management. Our data show that utilizing the expertise of GCs reduced test order errors, improved patient outcomes, and resulted in significant cost savings to the healthcare system.

August 10th 2017

From "Magic Bullets" to Precision Medicine—Ensuring More Patient-Centered Cancer Care

Joseph Alvarnas, MD

As we shift to the precision-medicine model of cancer care, it is essential to develop a scalable system that can deliver these care solutions in a patient-centered, economically sustainable way.

August 10th 2017

ICER Seeks Public Comment on Scoping Document for CAR-T Treatments

Surabhi Dangi-Garimella, PhD

The Institute for Clinical and Economic Review (ICER) has released a draft version of their scoping document that will compare the clinical effectiveness and value of 2 chimeric antigen receptor (CAR)-T cell treatments being reviewed by the FDA.

August 10th 2017

Vaccine for Glioblastoma Awarded Orphan Drug Status by FDA

Christina Mattina

MimiVax announced that its immunotherapy vaccine SurVaxM, which is being tested in clinical trials for glioblastoma, has been designated an orphan drug by the FDA.

August 9th 2017

Patient Engagement Is Mandatory at Our Table

Bonnie J. Addario Daryl Pritchard, PhD

The Bonnie Addario Lung Cancer Foundation has developed a registry that can serve as a repository for data on patients with lung cancer-a means to empower patients and assist care providers to deliver personalized medicine in a patient-centered manner.

August 9th 2017

Implementing an Oncology Precision Medicine Clinic in a Large Community Health System

Michael A. Thompson, MD, PhD Jennifer J. Godden, PharmD Scott M. Weissman, MS, CGC Deborah Wham, MS, CGC Amanda Wilson, MD Antony Ruggeri, MD Michael P. Mullane, MD James L. Weese, MD, FACS

Precision medicine is increasingly being utilized in oncology. Aurora Health Care has implemented Syapse software to integrate molecular data into the electronic health record to accommodate precision medicine findings.

August 9th 2017

Results of Phase 2 Study Investigating Luspatercept in MDS

Alison Rodriguez

The results of a phase 2 study that explored the effects of luspatercept in patients with lower-risk myelodysplastic syndromes (MDS) were presented at the 22nd Congress of the European Hematology Association by Acceleron Pharma Inc. The company is developing the drug with Celgene.

August 9th 2017

Study Investigates Molecular Profiling for Patients With Pancreatic Cancer

Alison Rodriguez

Treatment decisions could be assisted through molecular profiling, which would allow patients and oncologists to evaluate the biological features of the tumor.

August 8th 2017

Research Aims to Explain Paclitaxel's Ability to Both Treat and Spread Cancer

Christina Mattina

New research has identified a gene that enables paclitaxel to spread cancer to the lungs even as it shrinks tumors in the breast.

August 8th 2017

Medical World News®, August 2017

AJMC Staff

An update on the latest developments in the world of oncology care: product approvals, clinical developments, health policy changes, and more.

August 7th 2017

Targeted Oral Anticancer Agents and the Part D Donut Hole: Need for a New Policy Strategy?

Surabhi Dangi-Garimella, PhD

New research has found that the steady increase in the price of targeted oral anticancer medications is washing out the potential for savings that patients would experience in their out-of-pocket payments following closure of the Medicare Part D coverage gap.

August 7th 2017

NCI Researchers Discuss Prospects and Challenges of Treating Glioblastoma

Christina Mattina

Amidst news of Senator John McCain’s glioblastoma diagnosis, a recent discussion between 2 neuro-oncology researchers explored the reasons why this aggressive brain tumor is so difficult to manage, and outlined the ongoing investigations into possible therapies.

August 4th 2017

5 Developments With Cancer Immunotherapy

Surabhi Dangi-Garimella, PhD

There’s a lot happening in clinical practice with immunotherapy treatments: expanded indications for nivolumab and ipilimumab, biomarkers to judge patient response to combinations, and developments with CAR-T.

August 3rd 2017

Posttreatment Care in Breast Cancer: Oncologist vs PCP Roles

Surabhi Dangi-Garimella, PhD

Provider roles in team-based care in oncology need clarity, and now, results from a new study affirm the confusion experience by patients treated for breast cancer on who should lead their care posttreatment.

August 2nd 2017

Accelerated Approval for Nivolumab for DNA Repair—Deficient Advanced CRC

Surabhi Dangi-Garimella, PhD

The approval follows a review of phase 2 results from CheckMate-142.

August 2nd 2017

CAR-T Cells Can Increase Clinical Remission Rates in Multiple Myeloma Patients

Alison Rodriguez

The new immunotherapy of chimeric antigen receptor (CAR)-T cells has demonstrated the ability to increase clinical remission in multiple myeloma patients by targeting the B-cell maturation protein that participates in disease progression.

August 1st 2017

Enasidenib Approved for IDH2-Mutated Patients With Relapsed/Refractory AML

Surabhi Dangi-Garimella, PhD

Enasidenib (Idhifa), developed by Celgene and Agios, has been granted FDA approval in tandem with a companion diagnostic test to detect IDH-2 mutations.

August 1st 2017

Study Finds Rising Insurer Approvals for Cancer Clinical Trials Since ACA

Christina Mattina

After the Affordable Care Act (ACA) required private insurers to pay the standard-of-care costs for patients participating in approved clinical trials, the rate of patients cleared by their insurer to take part in early-phase oncology trials has increased, a new study has found.

July 31st 2017

The FDA's Roadmap for More Stringent Tobacco Regulation

Surabhi Dangi-Garimella, PhD

The FDA has announced a regulatory plan that could shift the trajectory on tobacco-related disease and death.

July 30th 2017

FDA Expands Approval of Yervoy for Metastatic Melanoma in Pediatric Patients

Alison Rodriguez

The FDA has expanded the indication of Bristol-Myers Squibb’s Yervoy (ipilimumab) to include the treatment of pediatric patients 12 years of age and older with unresectable or metastatic melanoma.

July 28th 2017

Breakthrough Therapy Designation for Venetoclax in AML

AJMC Staff

Venetoclax (Venclexta), in combination with low dose cytarabine, has been granted a breakthrough therapy designation for use in elderly, treatment-naive patients with acute myeloid leukemia (AML) who cannot handle intensive chemotherapy.

July 27th 2017

MYSTIC Trial Yields Disappointing Results for AstraZeneca's Durvalumab Combination in NSCLC

Christina Mattina

AstraZeneca announced that its immuno-oncology drug durvalumab, in combination with tremelimumab, failed to meet a progression-free survival endpoint in the MYSTIC trial in patients with metastatic non-small cell lung cancer (NSCLC).

July 27th 2017

The Crux: Correlating Surrogate Endpoints With Real-World Evidence in Oncology

Surabhi Dangi-Garimella, PhD

A new study has analyzed data from randomized controlled trials in oncology that used surrogate endpoints and measured their relation with treatment effectiveness and patient survival in the real world.

July 27th 2017

Genetic Tests Can Predict Tumor Aggressiveness and Help Treatment Decisions

Alison Rodriguez

Study used gene biomarker to identify which patients with colon cancer would not benefit from chemotherapy.

July 26th 2017

NCI Panel Discusses Importance of Research on Cancer Survivorship

Christina Mattina

During a panel hosted by the National Cancer Institute (NCI), patient advocates and survivorship experts discussed the strides made in the field of cancer survivorship research.

July 25th 2017

Mechanism for Checkpoint Inhibitor Resistance Identified in Invasive Bladder Cancer

Christina Mattina

Researchers have identified a cellular signaling pathway that when activated by mutations may prevent immune cells from infiltrating bladder tumors, thus making the cancer resistant to immune checkpoint inhibitors.

July 25th 2017

Cost-Effectiveness of a Patient Navigation Program to Improve Cervical Cancer Screening

Yan Li, PhD Erin Carlson, DrPH Roberto Villarreal, MD Leah Meraz, MA José A. Pagán, PhD

This study investigates the cost-effectiveness of a community-based patient navigation program to improve cervical cancer screening.

July 25th 2017

Low-Fat Dietary Patterns Potentially Linked to Lower Breast Cancer Mortality Rate

Alison Rodriguez

The Women’s Health Initiative Dietary Modification Trial examined the long-term influence of low-fat eating patterns on the breast cancer mortality rate.

July 25th 2017

Barriers to Recruiting ED Patients With Advanced Cancer for Palliative Care

Surabhi Dangi-Garimella, PhD

Patient refusal, symptom burden, and diagnostic disparities were identified as some of the most common barriers encountered when recruiting patients with advanced cancer for palliative treatment in the emergency department (ED).

July 25th 2017

Immune-Cell Numbers Determine Combination Immunotherapy Response in Melanoma Patients

Alison Rodriguez

The Journal of Clinical Investigation Insight recently published a study that analyzed 112 different melanoma tumors in attempt to correlate partially exhausted cytotoxic lymphocytes (peCTLs) and regulatory T lymphocyte (Treg) levels with response to combination immunotherapy.

...

66 67 68 69 70 71 72 73 74

...

184 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions